ProAssurance earnings in focus as Doctors merger nears close By Investing.com
ProAssurance is set to release its Q4 earnings, which could be its last as a standalone public company before its acquisition by The Doctors Company closes. Analysts expect earnings of $0.22 per share and revenue of $221.6 million, with investors closely watching its ability to maintain profitability amidst declining revenue and rising medical malpractice insurance rates. The merger, which has received shareholder approval, is expected to close in the first half of 2026.
ProAssurance earnings in focus as Doctors merger nears close By Investing.com
ProAssurance is expected to report its fourth-quarter earnings, potentially its last as a standalone public company before its acquisition by The Doctors Company. Analysts anticipate earnings of $0.22 per share on $221.6 million in revenue, with improving profitability despite projected revenue decline. Investors will focus on underwriting margins, expense management, pricing power, and updates regarding the merger, which is expected to close in the first half of 2026.
ProAssurance (PRA) Expected to Announce Earnings on Monday
ProAssurance (NYSE: PRA) is slated to announce its Q4 2025 earnings before market open on Monday, February 23, 2026, with analysts anticipating earnings of $0.22 per share. The company's stock opened at $24.54, near its 12-month high, and has a market capitalization of $1.26 billion. Analyst sentiment is generally cautious, with a consensus "Reduce" rating and an average target price of $25.00.
Credit Industriel ET Commercial Sells 80,720 Shares of ProAssurance Corporation $PRA
Credit Industriel ET Commercial has reduced its stake in ProAssurance Corporation (NYSE:PRA) by 24.2%, selling 80,720 shares and now possessing 252,275 shares valued at approximately $6.05 million. Despite this, several other institutions significantly increased their positions, leading institutional investors to collectively own about 85.58% of ProAssurance. Analysts maintain a cautious outlook with a "Reduce" consensus rating and a $25.00 price target, while the stock trades near its 52-week high with a market cap of $1.26 billion.
ProAssurance stock hits 52-week high at 24.63 USD By Investing.com
ProAssurance (PRA) stock has reached a new 52-week high of $24.63, reflecting strong investor confidence and a 67.63% total return over the past year. Despite its premium valuation with a P/E ratio of 37.37 and weak gross profit margins, the company maintains strong liquidity. Investors are awaiting its earnings report on February 23 for future performance insights.
ProAssurance stock hits 52-week high at 24.63 USD By Investing.com
ProAssurance (PRA) stock has reached a new 52-week high of $24.63, reflecting strong investor confidence and a 67.63% total return over the past year. Despite trading slightly above its Fair Value with a P/E ratio of 37.37, the company maintains strong liquidity with a current ratio of 2.36, although it faces weak gross profit margins. Investors are looking ahead to the upcoming earnings report on February 23rd, which could influence future performance.
ProAssurance stock hits 52-week high at 24.63 USD
ProAssurance Corp's stock has reached a new 52-week high at 24.63 USD, reflecting a 67.63% total return over the past year. Despite trading slightly above its Fair Value with a P/E ratio of 37.37, the company exhibits low price volatility and strong liquidity. Investors are advised to watch for its upcoming earnings report on February 23 for potential impacts on future performance.
Alpine Associates Management Inc. Purchases 403,807 Shares of ProAssurance Corporation $PRA
Alpine Associates Management Inc. significantly increased its stake in ProAssurance Corporation (NYSE:PRA) by 73.6% in the third quarter, purchasing an additional 403,807 shares. This makes ProAssurance the fund's 18th largest position, accounting for 1.4% of its investment portfolio, valued at $22.852 million. Other institutional investors also adjusted their holdings in ProAssurance, while Wall Street analysts currently rate the stock with a consensus of "Reduce" and a price target of $25.00.
ProAssurance (NYSE:PRA) Stock Price Passes Above 200-Day Moving Average - Should You Sell?
ProAssurance (NYSE:PRA) stock recently traded above its 200-day moving average. Despite this, analysts have a "Reduce" consensus rating with a $25.00 price target. Institutional investors have increased their holdings, but the article questions whether investors should sell.
ProAssurance Corp stock hits 52-week high at 24.44 USD By Investing.com
ProAssurance Corp (PRA) stock has reached a new 52-week high of $24.44, representing a 64.43% increase over the past year. This achievement underscores the company's strong market position and investor confidence in the insurance industry. Despite weak gross profit margins, the stock exhibits low volatility and solid liquidity.
ProAssurance (NYSE:PRA) Hits 52-Week High, Tracks NYSE Composite
ProAssurance (NYSE:PRA) has reached a 52-week high, indicating strong performance. The company specializes in property and casualty insurance, particularly professional liability for healthcare providers, and is included in the NYSE Composite. Its success is further bolstered by substantial institutional ownership and a focused operational strategy within its sector.
ProAssurance Corp stock hits 52-week high at 24.44 USD By Investing.com
ProAssurance Corp (PRA) stock has reached a new 52-week high of $24.44 USD, marking a significant 64.43% increase over the past year. This performance reflects strong investor confidence and the company's solid market position within the insurance industry. Despite its low volatility and healthy current ratio of 2.36, the company has relatively weak gross profit margins of 23.88%.
ProAssurance Corp stock hits 52-week high at 24.44 USD
ProAssurance Corp (PRA) stock has reached a new 52-week high of $24.44, marking a significant 64.43% increase over the past year. This performance highlights the company's strong market position and investor confidence in the insurance industry. The stock exhibits low volatility and solid liquidity, despite relatively weak gross profit margins.
Doctors Company agrees to buy ProAssurance for $25 a share
The Doctors Company has agreed to acquire ProAssurance for $25 per share. This acquisition aims to merge two significant players in the medical professional liability insurance market. The deal, valued at $25 per share, represents a strategic move for market consolidation and expanded service offerings.
Mitigating Healthcare Liability with Proactive Risk Management
Shep Tapasak, Chief Underwriting Officer at ProAssurance, emphasizes the critical role of proactive risk management in mitigating healthcare liability. He highlights the challenges large hospitals face in unifying risk management across diverse departments and varying litigation environments. Tapasak also discusses the impact of social inflation on jury awards and the need for healthcare providers to adapt their liability coverage, looking ahead to AI's promising role in improving care quality and safety.
ProAssurance Corporation (NYSE:PRA) Receives Average Rating of "Reduce" from Analysts
ProAssurance Corporation (NYSE:PRA) has received an average "Reduce" rating from six brokerages, with an average 12-month price target of $25.00. Institutional investors hold approximately 85.58% of the stock, with notable increases in holdings by Alliancebernstein L.P. and Millennium Management LLC. The company's stock opened at $24.05, has a market cap of $1.24 billion, and a P/E ratio of 36.99.
ProAssurance (NYSE:PRA) Shares Cross Above 200 Day Moving Average - Here's Why
ProAssurance (NYSE:PRA) shares have recently crossed above their 200-day moving average, trading as high as $24.17. The article highlights cautious analyst sentiment with a "Reduce" consensus and a $25.00 price target, alongside mixed signals from institutional ownership and company fundamentals. Key institutional investors have significantly adjusted their positions in the insurance provider.
ProAssurance (NYSE:PRA) Stock Price Crosses Above 200-Day Moving Average - Should You Sell?
ProAssurance (NYSE:PRA) stock price has risen above its 200-day moving average of $23.80, trading as high as $24.14 on Monday. Analysts currently rate the stock as "Reduce" with a consensus target price of $25.00, with five firms rating it Hold and one as Sell. The company, with a market cap of $1.24 billion, faces mixed analyst actions and thin liquidity profiles.
ProAssurance stock hits 52-week high at 24.41 USD
ProAssurance (PRA) stock reached a new 52-week high of $24.41 USD, marking a significant 45.11% increase over the past year. This achievement reflects strong market performance and investor confidence, supported by the stock's low price volatility with a beta of 0.12. Analysts have set a target price of $25 for the company.
Squarepoint Ops LLC Makes New $6.60 Million Investment in ProAssurance Corporation $PRA
Squarepoint Ops LLC recently invested $6.60 million in ProAssurance Corporation, acquiring 289,208 shares and establishing a 0.56% stake. Institutional investors now own 85.58% of the stock, with several firms increasing their positions. Despite these investments, analysts maintain a "Reduce" consensus rating with an average price target of $25.00, while the stock trades near $24.26.
LMR Partners LLP Has $18.41 Million Position in ProAssurance Corporation $PRA
LMR Partners LLP significantly increased its stake in ProAssurance Corporation (NYSE:PRA) by 287.2% in Q2, now holding 806,471 shares valued at $18.41 million. Despite this large investment, ProAssurance holds an average analyst rating of "Reduce" with a consensus price target of $25.00, driven by recent downgrades. The company's stock is trading near its 12-month high with a market cap of $1.25 billion and analysts predict an EPS of 0.8 for the current year.
ProAssurance stock hits 52-week high at 24.41 USD
ProAssurance (PRA) stock has hit a 52-week high of $24.41, marking a 45.11% increase over the past year and reflecting strong investor confidence. The company's stock generally trades with low price volatility, and analysts have set a target price of $25. This achievement highlights ProAssurance's continued growth trajectory in the market.
ProAssurance Nears Acquisition Finish Line as Shares Approach Buyout Price
ProAssurance Corporation's stock reached a 52-week high of $24.41, nearing its $25.00 per share acquisition price by The Doctors Company. The market's focus has shifted almost entirely to the deal's closing, with minimal volatility and traditional financial metrics taking a secondary role. The narrowing spread and low beta indicate a high probability of the acquisition being finalized soon.
ProAssurance stock hits 52-week high at 24.41 USD By Investing.com
ProAssurance Corp (PRA) stock has reached a new 52-week high of $24.41 USD, marking a significant 45.11% increase over the past year. This achievement highlights strong investor confidence and solid market performance, with InvestingPro data indicating low price volatility for the stock. Analysts have set a target price of $25 for PRA.
ProAssurance stock hits 52-week high at 24.41 USD By Investing.com
ProAssurance Corp (PRA) stock has surged to a new 52-week high of $24.41 USD, marking a significant 45.11% increase over the past year. This performance highlights strong investor confidence, with the stock historically showing low price volatility (beta of 0.12). Analysts have set a target price of $25, and InvestingPro offers further insights and ProTips for PRA.
ProAssurance (PRA) Price Target Increased by 10.29% to 25.50
This article reports that the price target for ProAssurance (PRA) has been increased by 10.29% to $25.50. No further details are provided about the reasons for this price target adjustment.
Marshall Wace LLP Boosts Stock Holdings in ProAssurance Corporation $PRA
Marshall Wace LLP significantly increased its stake in ProAssurance (NYSE: PRA) by 128.8% in Q2, bringing its total holdings to 443,081 shares valued at approximately $10.12 million. Other institutional investors like Russell Investments and Quantbot Technologies also expanded their positions. Despite high institutional ownership and recent earnings of $0.04 EPS, analysts currently hold a consensus "Reduce" rating with a $25 price target for ProAssurance.
ProAssurance (NYSE: PRA) approves executive cash incentives ahead of TDC merger
ProAssurance Corporation has approved executive cash incentive prepayments ahead of its merger with The Doctors Company (TDC). This decision, made by the Compensation Committee in consultation with TDC, aims to mitigate "excess parachute payment" tax issues under Section 280G by paying approximately 80% of expected 2025 annual cash incentives to named executive officers. The payments, totaling over $2.5 million for five key executives including CEO Edward L. Rand, Jr., were authorized on December 5, 2025, based on the likelihood of achieving 2025 performance targets.
Arrowstreet Capital Limited Partnership Reduces Position in ProAssurance Corporation $PRA
Arrowstreet Capital Limited Partnership significantly reduced its stake in ProAssurance Corporation (NYSE:PRA) by 23.2% in the second quarter, selling 162,594 shares and now owning 538,476 shares valued at $12.29 million. Despite this, other hedge funds, including Police & Firemen's Retirement System of New Jersey and Eisler Capital Management Ltd., increased their holdings in the insurance provider. ProAssurance's stock performance shows a market capitalization of $1.23 billion with analysts forecasting 0.8 EPS for the current year.
214,228 Shares in ProAssurance Corporation $PRA Acquired by Groupe la Francaise
Groupe la Francaise has acquired 214,228 shares of ProAssurance Corporation (NYSE:PRA), representing a stake valued at approximately $4.89 million and constituting about 0.42% of the company. Other institutional investors like XTX Topco Ltd, Wolverine Asset Management LLC, and Nuveen LLC have also recently invested in ProAssurance, contributing to 85.58% institutional ownership. Despite trading near its 52-week high, analysts currently hold a "Reduce" consensus rating for ProAssurance with an average price target of $25.00.
ProAssurance (PRA) Down 0.4% Since Last Earnings Report: Can It Rebound?
ProAssurance (PRA) shares have fallen 0.4% since its last earnings report, underperforming the S&P 500. The company's Q3 2025 adjusted operating income missed estimates due to weak underwriting performance, declining gross premiums, and elevated expenses, despite strong investment income growth. Analysts are now predicting a below-average return for the stock in the coming months, with estimates trending downward.
Skandinaviska Enskilda Banken AB publ Raises Stake in ProAssurance Corporation $PRA
Skandinaviska Enskilda Banken AB publ significantly increased its stake in ProAssurance Corporation by 760.8% in Q2, now owning 82,439 shares valued at $1.88 million. Other institutional investors also adjusted their positions, indicating active trading in the company. ProAssurance has a "Reduce" consensus rating from analysts with an average price target of $25.00, and reported $0.04 EPS on $220.02 million revenue last quarter.
ProAssurance Reports Results for Third Quarter 2025
ProAssurance Corporation reported net income of $1.4 million and operating income of $7.9 million for the third quarter of 2025. The company's Specialty P&C segment saw renewal premium increases of 8%, contributing to a cumulative increase of over 80% since 2018 in the medical professional liability market. ProAssurance also provided updates on its proposed merger with The Doctors Company, anticipating closing the transaction by June 30, 2026, pending regulatory approvals.
Mayer Brown advises The Doctors Company on $1.3 billion acquisition of ProAssurance Corporation
Mayer Brown advised The Doctors Company on its definitive agreement to acquire ProAssurance Corporation for $1.3 billion. The acquisition involves the nation's largest physician-owned medical malpractice insurer purchasing a specialty insurer with expertise in medical liability, products liability for medical technology and life sciences, and workers’ compensation insurance. The transaction is expected to close in the first half of 2026, pending customary closing conditions and regulatory approvals.
Market Fear: Will ProAssurance Corporation (PRK) stock remain on Wall Street radar - Weekly Investment Summary & Accurate Technical Buy Alerts
The requested article content could not be found due to a server error (404 - File or directory not found). It appears the resource may have been removed, renamed, or is temporarily unavailable.
Med-Mal Insurer ProAssurance to Go Private After $1.3B Purchase by The Doctors Co.
The Doctors Company has announced an agreement to acquire ProAssurance Corp. for $1.3 billion, taking the specialty insurer private. This acquisition will form a combined company with approximately $12 billion in assets and solidify The Doctors Company's position as a dominant force in the medical professional liability insurance market. ProAssurance stockholders will receive $25.00 in cash per share, representing a 60% premium.
ProAssurance being acquired by The Doctors Company
ProAssurance, a Birmingham-based insurance provider, is being acquired by The Doctors Company, a California-based medical professional liability carrier, for approximately $1.3 billion. Both companies were founded by physicians during the 1970s liability crisis and share similar philosophies. The acquisition, expected to close in the first half of 2026, will create the largest physician-owned medical professional liability carrier with pro forma net written premiums of about $2 billion.
ProAssurance Corp stock hits 52-week high at 24.14 USD
This article reports that ProAssurance Corp's stock reached a 52-week high of $24.14 USD. However, the article body itself contains an application error, suggesting the primary content failed to load.
Cannon Global Investment Management LLC Makes New $354,000 Investment in ProAssurance Corporation $PRA - MarketBeat
Cannon Global Investment Management LLC has made a new investment of $354,000 in ProAssurance Corporation (NYSE:PRA), acquiring 15,500 shares during the second quarter. This move comes as analysts, including Zacks Research, have upgraded ProAssurance to a "strong-buy" rating. The company, which has a market capitalization of $1.24 billion, reported earnings of $0.04 per share in its last quarterly report.
Medical Professional Liability Insurance Market to Hit $33.7 Billion by 2031, Growing at 10.8% CAGR - newstrail.com
The global medical professional liability insurance market is projected to reach $33.7 billion by 2031, growing at a CAGR of 10.8% from 2022 to 2031, according to a report by Allied Market Research. The market growth is driven by increased adoption of medical liability insurance and rising demand for security among healthcare professionals, exacerbated by the COVID-19 pandemic. Occurrence-based policies and the North American region currently dominate the market, while Asia-Pacific is expected to show the fastest growth.
Trading the Move, Not the Narrative: (PRA) Edition - news.stocktradersdaily.com
Stock Traders Daily's AI models indicate a neutral near and mid-term outlook for Proassurance Corporation (NYSE: PRA), with a long-term positive bias. The analysis highlights an exceptional 30.9:1 risk-reward setup targeting a 9.2% gain versus 0.3% risk. Multiple institutional trading strategies are provided, including position trading, momentum breakout, and risk hedging, alongside multi-timeframe signal analysis.
ProAssurance Corp. Experiences Revision in Stock Evaluation Amid Mixed Market Signals - Markets Mojo
ProAssurance Corp. (NYSE: PRA), a small-cap insurance company, has seen its stock price fluctuate and its evaluation revised. Despite mixed technical indicators, the company has significantly outperformed the S&P 500 over the past year, returning 60.04% compared to the index's 17.82%. The article highlights the company's resilience and competitive positioning within the insurance sector.
ALDOI to Hold Hearing on Planned ProAssurance Merger with FD Insurance
The Alabama Department of Insurance (ALDOI) will hold a public hearing on October 16 regarding the proposed merger between ProAssurance Indemnity Co. and FD Insurance Co. Both companies are domiciled in Alabama and have been involved in several financial transactions in recent years, including ProAssurance Group's 2021 acquisition of NORCAL, which had previously acquired FD Insurance. This merger is another step in the consolidation of these insurance entities, with ProAssurance Corp. itself having been acquired by The Doctors Company in April.
ProAssurance Corp. Experiences Revision in Its Stock Evaluation Amid Strong Performance Metrics
ProAssurance Corp., a small-cap insurance company, has undergone a valuation adjustment, with its stock price at $24.16. The company exhibits a P/E ratio of 33 and a price-to-book value of 1.13, outperforming the S&P 500 with year-to-date returns of 51.85%. While its EV to EBIT ratio is significantly negative, its PEG ratio of 0.21 suggests a potentially favorable growth outlook.
The Doctors Company and ProAssurance Announce Early Termination of the Hart-Scott-Rodino Waiting Period
The Doctors Company and ProAssurance Corporation announced the early termination of the Hart-Scott-Rodino waiting period for their pending acquisition. This satisfies one of the conditions for closing, with the acquisition expected to be completed in the first half of 2026, subject to remaining regulatory approvals. Both companies will continue to operate independently until the closing.
ProAssurance Stockholders Approve Its Proposed Acquisition by The Doctors Company
ProAssurance Corporation announced that its stockholders have overwhelmingly approved the proposed acquisition by The Doctors Company, with over 99% of votes in favor. The transaction remains subject to regulatory approvals, including the Hart-Scott-Rodino Act and insurance regulators in domicile states, and is expected to close in the first half of 2026. Upon completion, ProAssurance will become a wholly owned subsidiary of The Doctors Company and its stock will no longer be listed on the NYSE.
Birmingham insurance company acquired in $1.3 billion deal
Birmingham-based ProAssurance Corp. is being acquired by The Doctors Company, the nation’s largest physician-owned medical malpractice insurer, in a $1.3 billion deal. This acquisition will create a combined entity with $12 billion in assets. The deal is expected to close early next year, with provisions for employee severance if positions are eliminated within the first year after the transaction.
The Doctors Company enters $1.3bn deal to buy ProAssurance
The Doctors Company, a medical malpractice insurer, has agreed to acquire ProAssurance Corporation for $1.3 billion, with shareholders receiving $25 per share. Post-acquisition, ProAssurance will operate as a subsidiary of The Doctors Company, and its common stock will be delisted from the NYSE. The deal, expected to close in H1 2026, will create a combined entity with approximately $12 billion in assets.
ProAssurance Announces Election of Richard J. Bielen, C.P.A., and Staci M. Pierce, J.D., to Board
ProAssurance Corporation announced the election of Richard J. Bielen and Staci M. Pierce to its Board of Directors at its Annual Meeting of Shareholders on May 22. Shareholders also re-elected Bruce D. Angiolillo and Samuel A. Di Piazza, Jr., and approved the 2024 Equity Incentive Plan and the selection of Ernst & Young, LLP as the independent auditing firm. The company's board now consists of 10 members, and shareholders approved the compensation of named executive officers on an advisory basis.
ProAssurance Announces Fourth Quarter and Year-End 2023 Results Release and Teleconference
ProAssurance Corporation will release its fourth quarter and year-end 2023 financial results after market close on Tuesday, February 27, 2024. The company will host a conference call on Wednesday, February 28, 2024, at 10:00 AM ET to discuss the results and other relevant topics for investors. Dial-in and webcast details are provided for participation, along with replay information.
